08 October 2021
Due to extensive interest from the sector, we will be expanding the eligibility of the REDI Fellowship program so that smaller companies can apply for a Fellow.
The REDI Fellowship program provides companies in the medical technology, biotechnology and pharmaceuticals (MTP) sector with up to $250,000 per annum to bring academics and clinicians in-house for up to twelve months to work on priority medical research projects. A REDI Fellowship is intended to accelerate relationships, drive projects towards commercial outcomes and provide high-level commercial and entrepreneurial experience for the Fellow.
Until now, the program has been targeted at companies with 20 or more staff. However, given the level of interest from advanced smaller companies, we have expanded eligibility.
The revised criteria will require sponsor companies to have reached or surpassed the product (therapeutic, medical device, digital health) development inflection point and be able to provide high level support for the growth of the Fellow, with no minimum staff limit.
REDI Fellowships are designed to give researchers, academics, clinicians and MTP professionals industry experiences that differ from those provided by an employer, which is why sponsoring companies must be at a minimum product development stage rather than the discovery stage.
We encourage Australian industry organisations, including multinationals and ASX-listed companies, to consider applying for a Fellowship. The applications are currently open with next submission deadlines of 1 November 2021 and 1 March 2022.
Sponsors can select three types of Fellowships to apply for:
· One-year full time
· 6 - 12 months full time
· 6 – 12 months where the fellow spends 50% of time working with the sponsor.
The REDI Fellowship Program continues to foster greater collaboration between industry and the Australian research sector, which is critical for the growth and success of the MTP sector.